泊沙康唑、氟康唑预防移植物抗宿主病的严重。

文章的细节

引用

复制到剪贴板

乌尔曼AJ,立顿JH Vesole DH, Chandrasekar P,兰斯顿,Tarantolo SR, Greinix H,莫莱斯德代理W, Reddy V, Boparai N, Pedicone L, Durrant Patino H, S

泊沙康唑、氟康唑预防移植物抗宿主病的严重。

郑传经地中海J。2007年1月25日,356(4):335 - 47岁。

PubMed ID

17251530 (在PubMed

]

文摘

背景:侵袭性真菌感染发病率和死亡率的一个重要原因是在同种异体造血干细胞移植。方法:在国际、随机、双盲试验,我们比较口服泊沙康唑口服氟康唑对患者侵袭性真菌感染预防移植物抗宿主病(GVHD)接受免疫抑制治疗。主要终点是证明或可能的侵袭性真菌感染的发生率从随机化一天112固定治疗期的研究。结果:共有600名患者,301年被分配到泊沙康唑和氟康唑299。最后固定112天的治疗期,泊沙康唑被发现那么有效氟康唑在预防侵袭性真菌感染(发病率、5.3%和9.0%,分别;比值比,0.56;95%可信区间(CI), 0.30 - 1.07;P = 0.07),优于氟康唑在预防证明或可能的侵袭性曲霉菌感染(2.3% vs . 7.0%;比值比,0.31;95%可信区间,0.13 - 0.75; P=0.006). While patients were receiving study medications (exposure period), in the posaconazole group, as compared with the fluconazole group, there were fewer breakthrough invasive fungal infections (2.4% vs. 7.6%, P=0.004), particularly invasive aspergillosis (1.0% vs. 5.9%, P=0.001). Overall mortality was similar in the two groups, but the number of deaths from invasive fungal infections was lower in the posaconazole group (1%, vs. 4% in the fluconazole group; P=0.046). The incidence of treatment-related adverse events was similar in the two groups (36% in the posaconazole group and 38% in the fluconazole group), and the rates of treatment-related serious adverse events were 13% and 10%, respectively. CONCLUSIONS: Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. It was superior in preventing invasive aspergillosis and reducing the rate of deaths related to fungal infections. (ClinicalTrials.gov number, NCT00034645 [ClinicalTrials.gov].).

beplay体育安全吗DrugBank数据引用了这篇文章

药物

泊沙康唑